Recent Updates
Recently added Catalysts
ONC Positive Sentiment

BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6

Key Takeaway: BeOne Medicines Ltd. will announce its first quarter 2026 financial results on May 6, 2026, before market opening. Following the announcement, a live webcast will be hosted by management at 8:00 a.m. ET. The company emphasizes its commitment to developing accessible cancer treatments globally.
Price reaction · baseline $312.31 (2026-04-21 close) · hit after-hours · clean, no other ONC news in the window
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • BeOne Medicines is set to report its financial results, indicating ongoing operations.
  • The company is focused on developing innovative cancer treatments.
  • A live webcast will provide transparency and engagement with investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+15%
120-day peak, hindsight
Typical move
3.8%
average across 5 past catalysts
Lead asset
Tislelizumab
Phase 3 · Non-small Cell Lung Cancer

Full Press Release Details

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET.
The live webcast of this event can be accessed from the investors section of the Company’s website athttps://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website.

About BeOne Medicines

BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team of nearly 12,000 colleagues spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before.
To learn more about BeOne, please visitwww.beonemedicines.comand follow us onLinkedIn,X,FacebookandInstagram.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne’s plans, commitments, aspirations and goals related to BeOne’s medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled “Risk Factors” in BeOne’s most recent periodic report filed with the U.S. Securities and Exchange Commission (“SEC”) as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the SEC. All information in this press release is as of the date hereof, and BeOne undertakes no duty to update such information unless required by law.

Frequently Asked Questions

When will BeOne Medicines announce its Q1 2026 results?

BeOne Medicines will announce its Q1 2026 financial results on May 6, 2026.

What time is the BeOne Medicines webcast?

The live webcast will take place at 8:00 a.m. ET on May 6, 2026.

How can I access the BeOne Medicines webcast?

The webcast can be accessed from the investors section of BeOne's website.

What is BeOne Medicines focused on?

BeOne Medicines is focused on developing innovative treatments for cancer.

Last updated: Apr 22, 2026